Log In
Print
BCIQ
Print
Print this Print this
 

SNJ-1656, Y-39983

  Manage Alerts
Collapse Summary General Information
Company Mitsubishi Tanabe Pharma Corp.
DescriptionRho kinase (ROCK) inhibitor
Molecular Target Rho kinase
Mechanism of ActionRho kinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationGlaucoma
Indication DetailsTreat glaucoma
Regulatory Designation

Partner

Novartis AG; Senju Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today